메뉴 건너뛰기




Volumn 48, Issue 9, 2008, Pages 1063-1068

Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic

Author keywords

Dalbavancin; Monte Carlo simulations; Pharmacodynamics; Pharmacokinetics; Susceptibility

Indexed keywords

DALBAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

EID: 49649083562     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008321273     Document Type: Article
Times cited : (42)

References (17)
  • 1
    • 1242270459 scopus 로고    scopus 로고
    • Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates
    • Streit JM, Fritsche TR, Sader HS, Jones RN Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis. 2004 ; 48: 137-143.
    • (2004) Diagn Microbiol Infect Dis , vol.48 , pp. 137-143
    • Streit, J.M.1    Fritsche, T.R.2    Sader, H.S.3    Jones, R.N.4
  • 2
  • 3
    • 31744435192 scopus 로고    scopus 로고
    • Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program
    • Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis. 2006 ; 54: 149-153.
    • (2004) Diagn Microbiol Infect Dis , vol.54 , pp. 149-153
    • Jones, R.N.1    Stilwell, M.G.2    Sader, H.S.3    Fritsche, T.R.4    Goldstein, B.P.5
  • 4
    • 30744438311 scopus 로고    scopus 로고
    • Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): Initial results from an international surveillance protocol
    • Jones RN, Fritsche TR, Sader HS, Goldstein BP Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005 ; 17: 593-600.
    • (2005) J Chemother. , vol.17 , pp. 593-600
    • Jones, R.N.1    Fritsche, T.R.2    Sader, H.S.3    Goldstein, B.P.4
  • 5
    • 1442349121 scopus 로고    scopus 로고
    • Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers
    • Leighton A., Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004 ; 48: 940-945.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 940-945
    • Leighton, A.1    Ab, G.2    Dorr, M.B.3
  • 6
    • 27244442417 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide
    • Buckwalter M., Dowell JA Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005 ; 45: 1279-1287. Addendum
    • (2005) J Clin Pharmacol. , vol.45 , pp. 1279-1287
    • Buckwalter, M.1    Dowell, J.A.2
  • 8
    • 34248331649 scopus 로고    scopus 로고
    • In vivo pharmacodynamic activity of the glycopeptide antibiotic dalbavancin
    • Andes DR, Craig WA In vivo pharmacodynamic activity of the glycopeptide antibiotic dalbavancin. Antimicrob Agents Chemother. 2007 ; 51: 1633-1642.
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 1633-1642
    • Andes, D.R.1    Craig, W.A.2
  • 9
    • 0242468561 scopus 로고    scopus 로고
    • Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections
    • Seltzer E., Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003 ; 37: 1298-1303.
    • (2003) Clin Infect Dis , vol.37 , pp. 1298-1303
    • Seltzer, E.1    Dorr, M.B.2    Goldstein, B.P.3
  • 10
    • 27644549908 scopus 로고    scopus 로고
    • Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
    • Jauregui LE, Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005 ; 41: 1407-1415.
    • (2005) Clin Infect Dis , vol.41 , pp. 1407-1415
    • Le, J.1    Babazadeh, S.2    Seltzer, E.3
  • 15
    • 7444254040 scopus 로고    scopus 로고
    • Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory infections
    • Moise-Broder PA, Forrest A., Birmingham MC, Schentag JJ Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory infections. Clin Pharmacokinet. 2004 ; 43: 925-942.
    • (2004) Clin Pharmacokinet , vol.43 , pp. 925-942
    • Moise-Broder, P.A.1    Forrest, A.2    Birmingham, M.C.3    Schentag, J.J.4
  • 16
    • 0028831358 scopus 로고
    • The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: Focus on antibacterial agents
    • Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995 ; 28: 143-160.
    • (1995) Clin Pharmacokinet , vol.28 , pp. 143-160
    • Hyatt, J.M.1    McKinnon, P.S.2    Zimmer, G.S.3    Schentag, J.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.